Orbit Genomics, Imidex Technologies Enable Early Lung Cancer Detection
Imidex and Orbit Genomics have unveiled a strategic partnership. According to MobiHealthNews, the Imidex Orbit partnership allows the two healthtech companies to combine their expertise in reducing fatalities resulting from lung cancer.
Imidex is an AI-powered medical device firm that specializes in early lung cancer detection while Orbit Genomics is a DNA-sequencing technology company.
Precision in Detection
Imidex developed the FDA-approved VisiRad XR device. The device utilizes AI and is capable of detecting tiny lung nodules in chest X-rays. This procedure is much more scalable than the CT scans that high-risk individuals are asked to take.
According to Imidex, the VisiRad XR has an 83% sensitivity rate. The company holds that its platform can facilitate identification of suspicious masses in a wide population and refer more individuals to follow-up tests.
Orbit Genomics uses the OrbiSeq-L to diagnose lung cancer in patients who have pulmonary nodules detected through low-dose CT. The company plans to commence clinical trials on OrbiSeq-L
“By leveraging chest X-ray, we have the ability to opportunistically identify millions more patients with pulmonary nodules that are unwilling or not qualified to get a low-dose radiation CT scan,” Imidex CEO, Wes Bolsen said
Building Synergy
The Imidex Orbit Genomics partnership will allow the two tech companies to leverage the strength of their equipment to facilitate early cancer detection. The two companies plan to use Imidex’s VisiRad XR to identify lung nodules in patients. The results will be passed on to Orbit for testing of identified lung nodules with the help of OrbiSeq-L.
“Imidex’s technology is the top of the lung cancer identification funnel, utilizing chest X-rays rather than CT scans to detect potential cancer patients who might otherwise go undiagnosed. Orbit Genomics can then immediately test those identified lung nodule patients with OrbiSeq-L, providing highly specific insights from a simple blood sample into their condition and directing them to the most effective forms of care,” Orbit Genomics President, Dede Willis said in a statement.
Besides cancer detection, the OrbiSeq technology can be used to detect a wide range of diseases including neurological disorders and heart conditions.
Emerging Trend
The Imidex Orbit partnership to detect early lung cancer isn’t the first for the two companies. In July this year, Imidex collaborated with Spesana to monitor the impact of AI in boosting mass and lung nodule detection. The two companies are focused on quantifying downstream detection rates for lung cancer.
The companies are also working towards identifying high-risk patients for clinical trials. They do this through screening and evaluation of potential application of liquid biopsies that result from nodule detection.
Early this month, Orbit Genomics completed the CancerX Accelerator Program that’s focused on digital innovation and cancer intersection. Initiated by the US Department of Health and Human services, CancerX is focused on enhancing cancer innovation in the country.
The program involved hands-on learning and months of mentorship at the Moffitt Cancer Center.
Related Articles: How Revolutionary AI Model Detects Underlying Heart Attacks Risks
